07.03.2022 Vivoryon Therapeutics N.V.  NL00150002Q7

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference


 

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

07.03.2022 / 07:00
The issuer is solely responsible for the content of this announcement.


 

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
 

HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, will present at the following conference:


BioCapital Europe 2022
Date: March 10, 2022, 10:00 am CET
Venue: Amsterdam, The Netherlands
Presenter: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics N.V.

A webcast of the presentation will be available from March 11, 2022 via the "Presentations & Webcasts" page in the Investor Relations section on the Company's website at www.vivoryon.com and will be archived on the Company's website for 30 days following the conference.
 

###


About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com


Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: [email protected]


Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: [email protected]
 



07.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: [email protected]
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1295071

 
End of News DGAP News Service

1295071  07.03.2022 

fncls.ssp?fn=show_t_gif&application_id=1295071&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 10,76 0,00
EBITDA1,2 -13,67 -9,86 -7,68 -7,63 -15,87 -12,63 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 -117,38 0,00
EBIT1,4 -13,77 -9,96 -7,70 -7,72 -16,01 -12,79 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 -118,87 0,00
Jahresüberschuss1 -13,89 -8,01 -7,74 -7,82 -16,51 -12,66 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 -117,66 0,00
Cashflow1,7 -13,26 -12,12 -6,99 -11,61 -14,01 -11,26 0,00
Ergebnis je Aktie8 -1,82 -0,98 -0,94 -0,62 -0,83 -0,63 -0,51
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2QJV6 8,000 176,40
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -7,25
KBV KCV KUV EV/EBITDA
10,65 - 16,39 -12,95
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 22.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.06.2021 21.09.2021 04.11.2021 28.04.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,16% -35,34% -57,94% -56,52%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics N.V.  ISIN: NL00150002Q7 können Sie bei DGAP abrufen


Biotechnologie , A2QJV6 , 05Y , XETR:PB9